Authorized purpose: Prioritization and triage of non-contrast head CT cases with features suggestive of midline shift in individuals aged 18 years and older.
Clinical role
Passive case-level notification and worklist prioritization in parallel with standard-of-care interpretation; the device does not mark a location or triage findings other than MLS.
Images and patients
CT/CTA · Head/brain, for suspected midline shift (MLS)
Key limitation
Keep in mind: The device is limited to non-contrast head CT and suspected MLS in individuals aged 18 and older, with no user control to select other findings. Results are not for standalone clinical decision-making and are not intended to rule out MLS or preclude clinical assessment. The packet describes on-premise deployment without cloud-server interfacing.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Prioritization and triage of non-contrast head CT cases with features suggestive of midline shift in individuals aged 18 years and older.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Head/brain, for suspected midline shift (MLS) Input: Non-contrast head CT studies from individuals aged 18 years and older.
Who uses it?Intended users: Radiologists
What does the software produce?Output: Case-level passive notification available to a PACS/workstation for worklist prioritization when suspected MLS is identified; no preview image or marking of a specific location is provided.
What is its most important limitation?Key limitation: The device is limited to non-contrast head CT and suspected MLS in individuals aged 18 and older, with no user control to select other findings. Results are not for standalone clinical decision-making and are not intended to rule out MLS or preclude clinical assessment. The packet describes on-premise deployment without cloud-server interfacing.
Clinical takeaway. Clinical role: Prioritization and triage of non-contrast head CT cases with features suggestive of midline shift in individuals aged 18 years and older.
Evidence takeaway. Evidence from the reviewed source record: FDA retrospective, blinded, multisite validation used 300 US cases (102 positive and 198 negative) with majority ground truth from three US board-certified radiologists. The dataset included multiple CT manufacturers and a mean age of 59.46 years. Standalone sensitivity was 0.961 (95% CI: 0.903-0.985), specificity was 0.955 (95% CI: 0.916-0.973), AUROC was 0.983 (95% CI: 0.967-0.996), and mean processing time was 62.04 seconds (95% CI: 60.65-63.44); subgroup analyses were also performed.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Prioritization and triage of non-contrast head CT cases with features suggestive of midline shift in individuals aged 18 years and older.
Passive case-level notification and worklist prioritization in parallel with standard-of-care interpretation; the device does not mark a location or triage findings other than MLS.
Case-level passive notification available to a PACS/workstation for worklist prioritization when suspected MLS is identified; no preview image or marking of a specific location is provided.
The device is limited to non-contrast head CT and suspected MLS in individuals aged 18 and older, with no user control to select other findings. Results are not for standalone clinical decision-making and are not intended to rule out MLS or preclude clinical assessment. The packet describes on-premise deployment without cloud-server interfacing.
FDA retrospective, blinded, multisite validation used 300 US cases (102 positive and 198 negative) with majority ground truth from three US board-certified radiologists. The dataset included multiple CT manufacturers and a mean age of 59.46 years. Standalone sensitivity was 0.961 (95% CI: 0.903-0.985), specificity was 0.955 (95% CI: 0.916-0.973), AUROC was 0.983 (95% CI: 0.967-0.996), and mean processing time was 62.04 seconds (95% CI: 60.65-63.44); subgroup analyses were also performed.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA retrospective, blinded, multisite validation used 300 US cases (102 positive and 198 negative) with majority ground truth from three US board-certified radiologists. The dataset included multiple CT manufacturers and a mean age of 59.46 years. Standalone sensitivity was 0.961 (95% CI: 0.903-0.985), specificity was 0.955 (95% CI: 0.916-0.973), AUROC was 0.983 (95% CI: 0.967-0.996), and mean processing time was 62.04 seconds (95% CI: 60.65-63.44); subgroup analyses were also performed.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
EFAI Neurosuite CT Midline Shift Assessment System (MLS-CT-100) regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K241923
Samplen=300
IndependenceIndependence not established
K241923
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K241923. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Non-contrast head CT studies from individuals aged 18 years and older.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The device sends case-level notification to a PACS/RIS workstation for worklist prioritization and is deployed only on-premise; the packet states that it does not interface with cloud servers and does not establish a specific local interface or protocol.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes EFAI MLSCT, in the device deployment row of its comparison table, as deployed only on-premise. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Device Deployment d eployed only on-premise". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Case-level passive notification available to a PACS/workstation for worklist prioritization when suspected MLS is identified; no preview image or marking of a specific location is provided.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Case-level passive notification available to a PACS/workstation for worklist prioritization when suspected MLS is identified; no preview image or marking of a specific location is provided.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes EFAI MLSCT, in the device deployment row of its comparison table, as deployed only on-premise. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Device Deployment d eployed only on-premise". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The device sends case-level notification to a PACS/RIS workstation for worklist prioritization and is deployed only on-premise; the packet states that it does not interface with cloud servers and does not establish a specific local interface or protocol.
Ever Fortune.AI's investor information-security policy page states an implemented information security management system covering confidentiality, integrity, and availability, with security training and measurement targets; the page states the company has completed ISO 27001 certification and holds ISO/IEC 27701 PII-processor certification after independent third-party audit. The company's certification-milestones page lists ISO/IEC 27001:2022, ISO 22301:2019, ISO/IEC 27018:2019, and ISO/IEC 27017:2015.
Vendor-wide
Checked 2026-10-27
Vendor statement; certificates were not read. Applicant name variants (including uppercase and punctuation variants of Ever Fortune.AI Co., Ltd.) are bridged via the vendor's EFAI product naming and the owning domain everfortuneai.com.tw. Exact-release scope is not established.
ACR AI Central provides an exact-submission model card for EFAI Neurosuite CT Midline Shift Assessment System (MLS-CT-100); FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K241923 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support
Modality
CT/CTA
Anatomy
Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries
Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.
Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.